EmVenio Research Expands in the UK
With 10 mobile community research sites in the US, the move expands the organization’s international reach.
EmVenio Research, in collaboration with UK-based EMS Healthcare, will establish and operate commercial clinical trials in 10 mobile sites identified by EMS, across England, Wales, and Scotland. Each of the sites will be supported by a dedicated local workforce. EmVenio will be responsible for full clinical oversight, with principal and sub-investigators, and team leaders, and will oversee clinical trial operations and data management.
EmVenio currently operates research in 10 mobile community research sites across the United States.
Keith Austin, CEO of EMS Healthcare, said in press release, "A recent independent review of commercial clinical trials by Lord James O'Shaughnessy acknowledged the crucial role of mobile clinics in delivering trials with more diverse participation. We believe this initiative will attract more pharmaceutical sponsors to carry out trials, which will have a significant impact on both the U.K. economy and the health of our population."
Reference: EmVenio Research expands internationally with 10 research sites in the UK. DURHAM, N.C., June 20, 2023 /PRNewswire.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
